Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ)
CNY 12.14
(2.53%)
CNY 12.14
(2.53%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 8.28 Billion CNY | -11.47% |
| 2022 | 9.35 Billion CNY | -17.82% |
| 2021 | 11.38 Billion CNY | 16.39% |
| 2020 | 9.77 Billion CNY | 15.56% |
| 2019 | 8.46 Billion CNY | -1.9% |
| 2018 | 8.62 Billion CNY | -8.63% |
| 2017 | 9.44 Billion CNY | 18.18% |
| 2016 | 7.98 Billion CNY | 71.73% |
| 2015 | 4.65 Billion CNY | 29.64% |
| 2014 | 3.58 Billion CNY | 3.27% |
| 2013 | 3.47 Billion CNY | 17.83% |
| 2012 | 2.94 Billion CNY | 53.5% |
| 2011 | 1.92 Billion CNY | 4.03% |
| 2010 | 1.84 Billion CNY | 164.44% |
| 2009 | 698.31 Million CNY | 26.63% |
| 2008 | 551.47 Million CNY | -0.35% |
| 2007 | 553.43 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 8.05 Billion CNY | -0.77% |
| 2024 Q1 | 8.24 Billion CNY | -0.49% |
| 2024 Q2 | 8.11 Billion CNY | -1.5% |
| 2023 Q4 | 8.28 Billion CNY | -9.86% |
| 2023 FY | 8.28 Billion CNY | -11.47% |
| 2023 Q1 | 9.32 Billion CNY | -0.35% |
| 2023 Q2 | 9.21 Billion CNY | -1.17% |
| 2023 Q3 | 9.18 Billion CNY | -0.27% |
| 2022 Q4 | 9.35 Billion CNY | 0.2% |
| 2022 FY | 9.35 Billion CNY | -17.82% |
| 2022 Q2 | 10.94 Billion CNY | -2.05% |
| 2022 Q3 | 9.33 Billion CNY | -14.69% |
| 2022 Q1 | 11.17 Billion CNY | -1.85% |
| 2021 Q3 | 11.63 Billion CNY | 0.27% |
| 2021 FY | 11.38 Billion CNY | 16.39% |
| 2021 Q4 | 11.38 Billion CNY | -2.2% |
| 2021 Q1 | 9.87 Billion CNY | 1.03% |
| 2021 Q2 | 11.6 Billion CNY | 17.47% |
| 2020 Q1 | 9.55 Billion CNY | 12.94% |
| 2020 Q4 | 9.77 Billion CNY | -1.61% |
| 2020 FY | 9.77 Billion CNY | 15.56% |
| 2020 Q2 | 9.81 Billion CNY | 2.69% |
| 2020 Q3 | 9.93 Billion CNY | 1.27% |
| 2019 Q3 | 8.56 Billion CNY | 3.63% |
| 2019 Q4 | 8.46 Billion CNY | -1.17% |
| 2019 Q1 | 8.77 Billion CNY | 1.71% |
| 2019 Q2 | 8.26 Billion CNY | -5.83% |
| 2019 FY | 8.46 Billion CNY | -1.9% |
| 2018 Q1 | 9.25 Billion CNY | -1.97% |
| 2018 Q3 | 8.83 Billion CNY | -8.88% |
| 2018 FY | 8.62 Billion CNY | -8.63% |
| 2018 Q4 | 8.62 Billion CNY | -2.39% |
| 2018 Q2 | 9.69 Billion CNY | 4.78% |
| 2017 Q2 | 8.54 Billion CNY | -3.26% |
| 2017 Q3 | 8.62 Billion CNY | 0.99% |
| 2017 Q4 | 9.44 Billion CNY | 9.44% |
| 2017 FY | 9.44 Billion CNY | 18.18% |
| 2017 Q1 | 8.83 Billion CNY | 10.53% |
| 2016 Q1 | 4.69 Billion CNY | 0.88% |
| 2016 FY | 7.98 Billion CNY | 71.73% |
| 2016 Q4 | 7.98 Billion CNY | 5.48% |
| 2016 Q2 | 5.69 Billion CNY | 21.44% |
| 2016 Q3 | 7.57 Billion CNY | 32.88% |
| 2015 Q1 | 3.54 Billion CNY | -1.3% |
| 2015 Q4 | 4.65 Billion CNY | 1.41% |
| 2015 FY | 4.65 Billion CNY | 29.64% |
| 2015 Q2 | 5.08 Billion CNY | 43.65% |
| 2015 Q3 | 4.58 Billion CNY | -9.83% |
| 2014 Q3 | 3.46 Billion CNY | -3.01% |
| 2014 Q2 | 3.57 Billion CNY | 0.58% |
| 2014 Q1 | 3.55 Billion CNY | 2.35% |
| 2014 FY | 3.58 Billion CNY | 3.27% |
| 2014 Q4 | 3.58 Billion CNY | 3.42% |
| 2013 Q1 | 2.96 Billion CNY | 0.62% |
| 2013 FY | 3.47 Billion CNY | 17.83% |
| 2013 Q2 | 2.83 Billion CNY | -4.31% |
| 2013 Q4 | 3.47 Billion CNY | 1.61% |
| 2013 Q3 | 3.41 Billion CNY | 20.43% |
| 2012 FY | 2.94 Billion CNY | 53.5% |
| 2012 Q1 | 1.96 Billion CNY | 2.21% |
| 2012 Q2 | 2.08 Billion CNY | 6.12% |
| 2012 Q3 | 2.25 Billion CNY | 8.37% |
| 2012 Q4 | 2.94 Billion CNY | 30.6% |
| 2011 Q3 | 1.92 Billion CNY | 2.23% |
| 2011 Q1 | 1.7 Billion CNY | -7.42% |
| 2011 FY | 1.92 Billion CNY | 4.03% |
| 2011 Q4 | 1.92 Billion CNY | 0.05% |
| 2011 Q2 | 1.87 Billion CNY | 9.86% |
| 2010 Q3 | 754.96 Million CNY | 2.61% |
| 2010 FY | 1.84 Billion CNY | 164.44% |
| 2010 Q2 | 735.73 Million CNY | 0.0% |
| 2010 Q4 | 1.84 Billion CNY | 144.6% |
| 2009 Q4 | 698.31 Million CNY | 0.0% |
| 2009 FY | 698.31 Million CNY | 26.63% |
| 2008 FY | 551.47 Million CNY | -0.35% |
| 2007 FY | 553.43 Million CNY | 0.0% |